Support (INTERMACS) 1 and others 2 identified an increasing risk of pump thrombosis with the HeartMate II (HM II; Thoratec Corporation, Pleasanton, CA) continuous-flow device beginning around 2010 and continuing through 2013. The precise reasons for this trend toward an increased incidence of pump thrombosis remain unresolved, but may in part have been associated with gradual evolution of anti-coagulation management practices over the 6 years since the introduction of the HMII in the United States. 3, 4 Target international normalized ratio (INR) levels for warfarin management may have drifted lower 5 in recent years due to the recognized concerns for bleeding complications associated with mechanical circulatory support device therapy. 6, 7 After reports of a higher incidence of pump thrombosis, 1,2 clinicians began to re-evaluate anti-coagulation practices and other potential causes of pump thrombosis, including patient, management, device and implant proceduralrelated causes. [8] [9] [10] [11] With the general appreciation of the increased incidence of pump thrombosis requiring pump exchange, 2, 12 the mechanical circulatory support community at large has gradually evolved toward using somewhat higher target levels of INR in the management of warfarin therapy. 3, 10 In January 2015, the National Heart Lung Blood Institute (NHLBI) and the U.S. Food and Drug Administration (FDA) requested an updated INTERMACS analysis to examine whether rates of pump thrombosis were changing in response to efforts by the mechanical circulatory support community to address potential factors possibly related to pump thrombosis. To allow a sufficient clinical experience to occur since the initial reports of increased risk of pump thrombosis in the HMII, the date of implant for analysis was extended to July 1, 2014, with follow-up to October 1, 2014 to allow for a minimum of 3 months of follow-up for all patients.
Methods

INTERMACS database
The INTERMACS is a collaborative database sponsored by the NHLBI and collects outcomes data on FDA-approved durable (capable of patient discharged to home) mechanical circulatory support devices implanted in the United States. 13 INTERMACS data collection was initiated in June 2006 and, through January 2015, over 14,000 patients were entered into the database.
14 INTERMACS collects detailed demographic, implant and post-implant outcomes data from eventdriven episodes of care and at specific follow-up intervals.
Between April 2008 and June 30, 2014, a total of 11,123 HMII devices were implanted and recorded in the INTERMACS database. Of these, 9,808 adult (age 418 years) patients from 144 institutions received a primary HMII LVAD, either alone (9, 534) or with an additional right ventricular assist device (n ¼ 274) during the implant hospitalization. The group of 9,808 patients receiving a primary HMII implant formed the study group for this analysis.
Data collection
Demographic, hemodynamic, heart failure severity and co-morbidity data were collected before implantation. Major adverse events, including device malfunction, bleeding, infection, stroke and death, were collected when they occurred, with additional follow-up information obtained at the time of any hospital re-admission and at routine scheduled intervals at 1 week, 1 month, 3 months, 6 months, 12 months, 18 months and then every 6 months thereafter. Additional information was collected at the time of device explant for recovery, device exchange, cardiac transplantation or death.
Follow-up
Follow-up for all study events was continued through September 30, 2014, and was complete for approximately 95% of enrolled patients. Patients were censored at transplant or explant for recovery.
Definitions
Pump thrombosis was identified at the time of device explant, transplantation or death. The event of pump thrombosis was identified by the following definitions:
1. Pump exchange that was identified as being due to pump thrombosis (specified in explant reason).
2. Cardiac transplantation with device removal in which pump thrombosis was identified.
3. Pump thrombosis suspected (via the device malfunction form) within 60 days before death, in which the death form specified that the device was not functioning normally at the time of death.
Pump thrombosis suspected (via the device malfunction form)
within 60 days before pump exchange.
within 60 days before transplantation.
within 60 days before pump explant due to "recovery."
When device thrombosis was not specifically identified at the time of pump exchange, transplant or death, all relevant forms at the time of transplant, pump exchange or death plus the relevant forms within the preceding 60 days were reviewed by 3 independent investigators. A consensus was achieved to determine whether the identified event was associated with no, possible, probable or definite pump thrombosis. Those events determined to be probable or definite pump thrombosis were included as a pump thrombosis event in this analysis.
Statistical analysis
Kaplan-Meier actuarial depictions were generated to explore differences in freedom from pump thrombosis over time. Possible risk factors for pump thrombosis were examined by multivariable analysis in the hazard function domain. 15 Risk factors were examined in the early and constant phase with Time 0 set at time of implant (for pre-implant risk factors). The variables entered into the multivariable analysis are listed in Appendix 1. An additional multivariable analysis was undertaken to examine both pre-implant variables as well as variables during the first month after implant. Time 0 in this analysis was 1 month post-LVAD implant. The variables for this analysis are listed in Appendix 2. For the KaplanMeier actuarial depictions, patients were censored at the time of pump explant, pump exchange or transplantation for reasons other than pump thrombosis. Patients were also censored at time of death if death was not considered related to pump thrombosis. Standard competing outcomes methodology 16 was employed for an additional analysis to examine the mutually exclusive events of transplantation without pump thrombosis, death without pump thrombosis, explant for recovery without thrombus, and the event defined as pump thrombosis (see definitions). Competing outcomes depictions were generated by year of implant, and the sum of the proportion of patients in each mutually exclusive event totaled 1.0 for any given time post-implant.
Results
Patient survival
Among the 9,808 primary HMII implants, patient survival exceeded 80% each year since 2008. Patient survival by year did not differ over the 6-year study period (Figure 1 ).
Pump thrombosis
Among the 9,808 primary HMII implants, 812 pump exchanges for thrombosis occurred after the primary implant, and 100 subsequent pump exchanges for pump thrombus occurred after the initial exchange (total of 912 pump exchanges for pump thrombosis). A total of 955 pump thrombosis events were identified at time of pump explant, heart transplantation or death. Freedom from pump thrombosis was 95% at 6 months, 93% at 12 months and 89% at 24 months ( Figure 2 ). The hazard function (instantaneous risk of pump thrombosis) peaked at approximately 2 months and declined rapidly thereafter, merging with a constant hazard at about 9 months after implantation.
Actuarial freedom from pump thrombosis, stratified by year of implant (Figure 3 
Modeling of pump thrombosis by year of implant
Using the data set consisting of the 9,808 primary HMII implants, the association between pump thrombosis and the year of implant was modeled in the hazard domain (Table 1) . Implant date transformations were identified in both the early and constant phases. The resultant parametric depiction of implant by year ( Figure 4 ) closely approximated the actuarial findings ( Figure 3) , with the parametric point estimates of freedom from pump thrombosis at various intervals mimicking those same observations in the stratified actuarial depiction. The hazard function (events per month) revealed a decrease in the risk of pump thrombosis in 2014 compared with 2012 or 2013, which was most apparent during the first 3 months post-implantation ( Figure 5 ).
Pre-implant risk factors for pump thrombosis
Implant era
By multivariable analysis in the hazard function domain, pre-implant risk factors in the early and constant phase were 98%  91%  89%  4  3  6  6  8  9  0  0  2  98%  98%  93%  87%  2010  1581  118  98%  96%  88%  84%  2011  1838  173  96%  94%  85%  ---2012  2183  236  93%  90%  ------2013  2036  191  92%  89%  -- 
Figure 3
Actuarial freedom from HMII pump thrombosis, stratified by year of implant. The error bars indicate Ϯ1 SE. The actuarial point estimates are in the table. Note that the y-axis scale goes from 80 to 100. identified ( Table 2 ). Year of implant was again identified as a risk factor in both the early and constant phase.
The era effect was further examined by comparing the incidence of risk factors in 3 eras (Table 3) . Although the proportion of various risk factors was significantly different among eras, the magnitude of differences was small and unlikely to be of clinical importance. When the overall risk model was applied to each of the 3 eras (see Table 3 ), the predicted number of events was close to the number generated by the actuarial depictions. These sub-analyses suggest little difference in the patient risk profiles for pump thrombosis between eras.
Age at implant
Age was identified as a risk factor in the early phase, and this finding is supported by the stratified actuarial depiction of freedom from pump thrombosis according to age groups ( Figure 6 ). Those o40 years of age were at increased risk of thrombotic events and, among those 470 years old, thrombosis was uncommon. The mean age at implant has gradually increased over the past 6 years, from 57 years in 2010 to nearly 59 years of age in 2014. This corresponds with a progressive increase in the proportion of patients targeted for destination (permanent) LVAD therapy (35% in 2010, 45% in 2012 and 55% in 2013). The freedom from pump thrombosis among destination therapy (DT) patients has followed the same pattern by year as seen for the overall group ( Figure 7 ). For patients o40 years of age, the same general trends according to year of implant were observed as in the overall group.
Female gender
Female gender was associated with increased risk of pump thrombosis in the early phase, but the actuarial freedom from pump thrombosis in females was only 1% lower than males at 6 months. Females did have an increased proportion of small ventricular chambers (left ventricular end-diastolic dimension o4.5 cm) compared with males (37 of 1,420 [2.6%] vs 74 of 5,507 [1.3%]).
Body mass index
Patients with higher body mass index were at a progressively increased risk of pump thrombosis, which was particularly apparent in those with a body mass index (BMI) 430 (Figure 8 ). For a patient with a BMI of 35, the probability of pump thrombosis within 24 months peaked at about 15% in 2013.
History of non-compliance
A history of repeated non-compliance is a risk factor that was supported by the univariate actuarial depiction, in which noncompliant patients had a 5% lower freedom from pump thrombosis compared with compliant patients at 6 months. In the hazard domain, the association between pump thrombosis and year of implant was modeled. No specific hypothesis was tested. Note: Implant date is the number of years since January 1, 2000 (e.g., an implant date of June 30, 2012 would be rescaled to 12.5 years). 
Figure 4
Parametric solution of the hazard model (see Table 1 ) for the effect of implant year on freedom from HMII pump thrombosis. The dashed lines indicate the 70% confidence limits. The table contains the parametric point estimates. Note that the y-axis scale goes from 80 to 100. Hazard Function
Figure 5
Hazard curves (based on the model in Table 1 ) for the risk of HMII pump thrombosis over time, stratified by year of implant. The dashed lines indicate 70% confidence limits. Note that the hazard for pump thrombosis for the first half of 2014 falls below that for 2012 and 2013.
Other risk factors
The remaining risk factors identified by multivariate analysis (see Table 2 ) were all associated with small but significant decrements in freedom from pump thrombosis as viewed in stratified actuarial depictions. Blood group non-O was a risk factor for pump thrombosis in the early phase.
Institutional variability
When the 50 highest volume centers for HMII implants were entered into the multivariable analysis, 8 institutions were identified as significantly more likely to experience pump thrombosis in the early phase, and 7 different institutions were identified as independently associated with pump thrombosis in the constant phase (p o 0.05). Only 4 institutions were identified with a slightly lower risk of pump thrombosis, and this was observed in the constant phase.
Among the 8 hospitals with higher risk in the early phase, the actuarial incidence of pump thrombosis by 6 months was 21% during 2013, as compared with 14% for the 7 hospitals with higher risk in the constant phase and 3% for the 4 hospitals with low risk in the constant phase. The 35 hospitals without increased risk in the early or constant phase had an actuarial incidence of pump thrombosis at 6 months of 7% during 2013. Data expressed as number or mean (%).
Additional risk factors during the first month postimplant
The multivariable analysis was performed using additional covariates during the first month (see Appendix 2) and setting Time 0 as 1 month post-implant. The additional risk factor identified during the first postimplant month was a higher lactate dehydrogenase (LDH) level at 1 month (hazard ratio ¼ 1.16, p o 0.0001, early phase hazard). The progressive increase in risk for every 100 mg% increase in LDH is depicted in Figure 9 . When examined as a dichotomous variable (LDH above and below 600 mg%), the cumulative risk of pump thrombosis by 6 months was approximately 20% when LDH was 4600 mg% at 1 month ( Figure 10 ).
Competing outcomes
By competing outcomes analysis, the actual incidence of pump thrombosis by 12 months was 2% in 2009 and 9% in 2013. This corresponds to a 12-month predicted incidence of thrombosis by the actuarial method of 2% in 2009 and 11% in 2013 (see Figure 3) . The actual percent of pump thrombosis identified within 6 months of implant showed a peak of 8% in 2013, decreasing to 5% during the first half of 2014 ( Figure 11 ).
Recurrent pump thrombosis
The freedom from subsequent pump thrombosis after pump exchange for any reason is depicted in Figure 12 . The cumulative risk of subsequent pump exchange increased progressively after each successive pump exchange. However, the likelihood of subsequent pump thrombosis events was significantly different depending upon whether the initial pump exchange was for pump thrombosis or another indication ( Figure 13 ). Thus, a subsequent pump exchange for thrombosis was much more likely if the initial indication P(overall) < 0.0001
Figure 6
Actuarial freedom from HMII pump thrombosis, stratified by age group. The error bars indicate Ϯ1 SE. The dashed lines indicate no further events during follow-up. The figure table contains the actuarial point estimates.
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Figure 7
Actuarial freedom from HMII pump thrombosis among patients with a strategy of destination therapy, stratified by implant year (n ¼ 3,958). The depiction is as in Figure 6 . < 20  512  26  97%  96%  93%  92%  90%  20-30  5599  396  96%  94%  91%  87%  84%  > 30  3588  385  94%  91%  86%  81%  77%  Missing  109  5  99%  95%  92% -------P(overall) < 0.0001
Figure 8
Actuarial freedom from HMII pump thrombosis, stratified by body mass index (BMI) group. The depiction is as in Figure 6 . 
Figure 9
Actuarial freedom from HMII pump thrombosis, stratified by maximum lactate dehydrogenase (LDH) at 1 month (Ϯ2 weeks) post-implant. Note that Time 0 in this depiction is 1 month post-implant.
for pump exchange was thrombosis, and it was much less likely if the initial indication for pump exchange was for an indication not related to pump thrombosis.
Successive pump exchange for pump thrombosis carried major risk of mortality within the next year ( Figure 14) . Among patients undergoing an initial pump exchange for thrombosis, the subsequent 1-year mortality was 30%.
Discussion
Pump thrombosis
The dilemma of LVAD pump thrombosis reflects the complex interaction of the coagulation system, biomaterials and aberrant flow conditions. 17 The interplay between clinical practice, recognition of pre-implant risk, and limitations in technology all are critical to understanding how this phenomenon has come to the attention of clinicians and why such variability in expression of rates and prevalence has occurred. This INTERMACS analysis and modeling suggest that the risk of pump thrombosis, particularly in the early phase (about 6 months), appears to have decreased during the first half of 2014 compared with the previous 2 years. If 
Figure 10
Actuarial freedom from HMII pump thrombosis, stratified by lactate dehydrogenase (LDH) levels above or below 600 mg%. The depiction is as in Figure 9 . Percent Thrombosed pumps by 6 months post implant
Figure 11
Bar chart indicating the actual observed percent of pump thrombosis by 6 months post-HMII implant, stratified by implant year along the horizontal axis. 
Figure 12
Actuarial freedom from HMII pump thrombosis stratified by the number of HMII implants for a given patient. The upper curve indicates freedom from pump thrombosis after the initial implant, the second curve indicates the freedom from pump thrombosis after the first pump exchange, the third actuarial curve indicates freedom from pump thrombosis for the second pump exchange, and so forth. 
Figure 13
Actuarial freedom from HMII pump thrombosis, stratified by the cause of explant of the first pump. Thus, the upper curve indicates freedom from pump thrombosis for the primary device; the second curve indicates freedom from subsequent pump thrombosis when the first explant was for a reason other than pump thrombosis; and the third curve represents freedom from pump thrombosis when the first pump exchange was related to pump thrombosis. in patient profiles during 2014, our modeling suggests a favorable impact upon potential causative factors associated with pump thrombosis. The modest reduction of observed pump thrombosis at 6 months during 2014 has occurred in a milieu of heightened intensity of anticoagulation management, greater surgical awareness of optimal pump implantation and positioning and pump speed management. 18, 19 Thus, one may speculate that current thrombosis risk-mitigation strategies have contributed to reducing but not eliminating the increased thrombosis risk observed since 2011.
The modeling described has important limitations and uncertainties. Although we were able to mathematically mimic the actuarial curves with our parametric models, it is important to note that the 2014 cohort represents only the first 6 months of the 2014 experience with follow-up ranging from 3 to 9 months. We will have greater clarity about the accuracy of this model when complete data from the entire year of 2014 are available for analysis.
Risk factors for pump thrombosis
Implant era
The multivariable analysis continues to identify era of implant as a major risk factor for pump thrombosis, both in the early and constant phase (see Table 3 ). The multivariable model was not able to fully account for the possible improvement in 2014. Even with the rapid evolution toward more rigorous control of INR and resetting the target to a higher level in most institutions (in concert with 2014 Thoratec recommendations 10 ), the reduction in pump thrombosis has, at best, returned to the levels observed in 2011, and clearly above the levels observed in 2008 to 2010. 20 The precise reasons remain obscure, but may include improved diagnosis and reporting of pump thrombosis and recognition of the importance of LDH monitoring. The comparison of risk factors between eras and the application of the overall multivariable model to each era suggest that no major changes in the patient population have occurred that would predict a greater or lesser propensity for pump thrombosis. The contribution of possible subtle changes in pump manufacturing that may account for an increased susceptibility to pump thrombosis is also unknown.
Age
Younger age has previously been identified as a risk factor for pump thrombosis. 1 Regarding the possibility that older age is somewhat protective against the risk of pump thrombosis, the average age at implant was essentially unchanged between 2013 and 2014 (58.7 vs 58.8 years), when a possible reduction in pump thrombosis occurred.
Female gender
Female gender was associated with a higher incidence of pump thrombosis, but the gender differences were small. We speculate that this small but significant difference may relate to the slightly larger proportion of females with smaller ventricular dimensions and, possibly, the more restricted pump space available (on average) under the costal margin in females, both of which could challenge perfect inflow cannula placement.
Higher BMI
The incremental risk of higher BMI was also established in our previous analysis. 1 Of interest, this risk factor was only evident in the constant phase of hazard. It remains speculative whether obesity portends a relatively hypercoagulable state. Obesity may be associated with a higher risk of pump migration in the pre-peritoneal pocket with subsequent pump malposition. Pump fixation in the preperitoneal pocket has been suggested as a risk mitigation step for pump thrombosis. Malposition in this group of patients could result in disturbed laminar flow at the inflow portion of the pump.
Possible contributors to a hypercoagulable state
Given the intrinsic tendency of this and other current generation continuous-flow pumps to develop fibrin deposition around the bearings, it is of interest that several of these risk factors could contribute to a chronic tendency toward increased coagulability. A history of smoking and chronic pulmonary disease may contribute to relative polycythemia or higher platelet reactivity in the case of smoking. 21 Higher pre-implant hemoglobin levels and platelet counts could also tip the balance toward stasis within areas of greater turbulent flow within the pump. 
Figure 14
Actuarial survival stratified by the original cohort and the first and second pump exchange for thrombosis.
Non-O blood group
Our analysis shows that pump thrombosis was more common in patients with non-O blood groups. Individuals with blood types A, B or AB (non-blood group O) have been reported to demonstrate greater coagulability than type O individuals. 22 Higher levels of von Willebrand factor and Factor VIII have been reported in individuals with all non-O phenotypes compared with blood group O, and higher levels have been linked to venous thromboembolism. 22, 23 Severe right heart failure The highly detrimental impact of right heart failure and the need for short-or long-term right ventricular support post-VAD on survival has been clearly documented.
14 Its identification as a risk factor for thrombosis would be expected if persisting right ventricular (RV) dysfunction after RVAD support resulted in decreased LVAD filling, lower LVAD output and greater degrees of in-pump stasis. Adequate laminar flow across the blood-washed inflow bearing of the pump is critical for heart transfer, which, if not maintained, can lead to bearing thrombus formation.
History of non-compliance
The association of non-compliance with pump thrombosis underscores the importance of strict adherence to the oral anti-coagulant regimen and close clinical follow-up, particularly during the first 6 months post-implant. Noncompliance is represented by not only the domain compliance with anti-coagulant medications, but also lack of care for the device, failure to communicate with the care team for regular outpatient assessments of LVAD parameters, and failure to report subtle signs of impending alarm conditions.
Institutional variability
When examining institutional variability, we examined those centers with the highest volume of HMII implants, which did not necessarily equate to the overall highest volume of continuous-flow device implants, as there was also considerable center variability in the proportion of axial-flow and centrifugal-flow pumps being implanted. Although only the 50 highest volume hospitals were selected for this part of the analysis, the identification of 8 higher risk hospitals in the early phase and 7 in the constant phase suggests that the techniques of implantation and/or patient management at some hospitals may have contributed to the likelihood of pump thrombosis.
Additional risk factors during the first month postimplant
Several publications have identified the prognostic significance of marked elevation of LDH early post-implant as a predictor of subsequent pump thrombosis.
1,24-26 Although we analyzed LDH as a continuous variable, we recognize that a "threshold" of LDH elevation (perhaps 500 or 600 mg %) (see Figure 14 ) may indicate sufficient fibrin deposition around an inflow bearing to generate major hemolysis. The marked predictive value of LDH exceeding 600 mg% at 1 month was identified despite the differing assays for LDH among institutions. The finding of high LDH during the first month represents a potentially significant opportunity to intervene with more intensive anti-coagulation or fibrindisruptive measures that could possibly reverse early fibrin deposition and alter the trajectory toward eventual pump exchange.
Implications of actuarial vs competing outcomes depictions
The use of actuarial versus competing outcomes depictions 16 is dependent on the research question. The actuarial method basically asks, "What is the probability of an event (in this case, pump thrombosis) assuming that other potential outcomes do not occur first"? In the context of this study, the actuarial freedom from an initial pump thrombosis examines the likelihood over time of this event, assuming that the patient does not undergo heart transplantation without impending pump thrombosis, pump explant for indications other than pump thrombosis, or death unrelated to pump thrombosis.
Competing outcomes depictions acknowledge that other competing outcome events may occur, potentially before the inherent risk of pump thrombosis is manifest as an event. Thus, the competing outcomes depiction is more reflective of "real-world" experience, in that it accounts for other mutually exclusive events that may occur. 16 Therefore, if the goal is to examine the actual incidence of initial pump thrombosis in a given time period, competing outcomes depictions would be the appropriate statistical methodology. However, to depict the underlying tendency for a pump to undergo thrombosis, the most relevant information is obtained from the actuarial depiction.
For example, if an actuarial depiction indicates a 10% probability of pump thrombosis within 6 months, this is reflective of the inherent tendency for pumps to have thrombosis, assuming that transplantation, death or explant for other reasons does not occur. In an institution or in a geographic area where very few patients on VAD support undergo transplantation within the first 6 months, the competing outcomes "incidence" of pump thrombosis by 6 months may be very similar to the actuarial estimate. However, if instead 80% of patients on VAD support were able to undergo heart transplantation within the first 3 months, the competing outcomes "incidence" of pump thrombosis would be very much lower. Thus, the KaplanMeier actuarial depiction more accurately reflects the tendency for pumps to undergo thrombosis, whereas the competing outcomes depiction indicates the actual incidence of pump thrombosis given the likelihood of other competing outcome events.
Recurrent pump thrombosis
We have previously documented 1 the increased risk of death associated with repeated pump exchanges. The present analysis suggests that the susceptibility to needing a subsequent pump exchange for thrombosis is greatly increased if the initial indication for exchange was for pump thrombosis (versus infection or electronic device malfunction). This is perhaps predictable given the practice of most surgeons to routinely change the pump alone, realizing that the vast majority of pump thrombus develops within the pump itself. 18 However, subtle imperfections in inflow cannula alignment or outflow graft position, which could predispose to abnormal flow patterns within the pump, 19 would not be corrected by pump exchange alone. This underscores the importance of appropriate interrogation of inflow cannulation position and the outflow graft pathway when planning the surgical details of pump exchange. Recurrent pump thrombosis events could also represent undetected hypercoagulability disorders in a patient with repeated events.
Study limitations
The INTERMACS database chronicles and analyzes the world's largest experience with continuous-flow ventricular assist devices and, in this analysis, the largest experience with the HMII pump. Our actuarial, parametric and multivariable models benefit from rigorous data entry, extensive monitoring of data completeness and robust data analysis. Despite these major advantages of INTERMACS procedures, this analysis has notable limitations. Pump thrombosis is documented in slightly 450% of thrombosis events. The remainder of pump thrombosis events were inferred from additional documentation relating to device malfunction. Despite confirmatory conclusions on individual events from 3 experienced INTERMACS clinical scientists, the assignment of "probable thrombosis" as a pump thrombosis event interjects some uncertainty. However, because the same criteria for a "pump thrombosis event" were applied across all years, it appears unlikely that the identification of pump thrombosis events differed very much throughout the years of analysis.
It is also probable that this analysis represents an underreporting of pump thrombosis, as only pump thrombosis events extreme enough to result in pump exchange, death or urgent cardiac transplantation were included as events. Less obvious forms of pump thrombosis, such as those suggested by elevated LDH and plasma free hemoglobin alone or suspected thrombosis treated with anti-coagulation or lytic therapy, would not be identified by this analysis. Thus, reporting of hemolysis with a hemolysis event form was not used to identify occurrences of pump thrombosis in the absence of a device malfunction form. It is also possible that the threshold for pump exchange for thrombosis decreased somewhat in recent years (leading possibly to an increase in observed incidence of thrombosis), although that would likely not explain the observed decrease in pump thrombosis events during the first half of 2014.
From an analysis of nearly 10,000 HMII implants since 2008, we conclude the following:
1. The small but progressive increase in the incidence of pump thrombosis observed between 2010 and 2013 with the HMII has reversed somewhat in the first half of 2014, returning to the levels seen in 2011. However, the incidence of pump thrombosis has not returned to the low levels of 2008 to 2010. 2. Patient survival with this device remains good: 480% at Year 1 and 70% at Year 2. 3. Higher body mass index, younger age, history of noncompliance and severe right heart failure predict a higher incidence of pump thrombosis during the first 6 months. 4. Elevated LDH during the first month of Z600 mg% predicts a 20% incidence of pump thrombosis within 6 months. This may provide an opportunity for early intervention strategies. 5. Recurrent pump thrombosis after the first pump exchange is more likely if the indication for first pump exchange was for pump thrombosis, suggesting that patient or pumpplacement factors are etiologically important. The 1-year mortality of 30% after pump exchange for thrombosis underscores the seriousness of this complication.
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